David S. Dickens

机构：University of Iowa · ORCID：0000-0001-8821-6022

发表论文 95 篇 · 总被引 2568 次 · h-index 22

代表论文

• Menin inhibition with revumenib for NPM1 -mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study (2025 · Blood · 被引 63)
• Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia (2025 · Blood · 被引 40)
• Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia (2024 · Blood · 被引 16)
• Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study (2025 · Blood · 被引 5)
• A soaring price, a silent fight: Thioguanine portends new access barriers to life‐saving treatments for children with cancer (2024 · Pediatric Blood & Cancer · 被引 4)
• Factors Associated With Symptom Burden Among Pediatric Patients With Cancer (2025 · JCO Oncology Practice · 被引 3)